A detailed history of Johnson Financial Group, Inc. transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Johnson Financial Group, Inc. holds 166 shares of HALO stock, worth $8,134. This represents 0.0% of its overall portfolio holdings.

Number of Shares
166
Previous 22 654.55%
Holding current value
$8,134
Previous $1,000 800.0%
% of portfolio
0.0%
Previous 0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$51.3 - $64.42 $7,387 - $9,276
144 Added 654.55%
166 $9,000
Q2 2024

Aug 14, 2024

BUY
$37.81 - $52.4 $831 - $1,152
22 New
22 $1,000
Q4 2023

Feb 09, 2024

BUY
$33.32 - $42.1 $17,726 - $22,397
532 New
532 $19,000

Others Institutions Holding HALO

About HALOZYME THERAPEUTICS, INC.


  • Ticker HALO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 139,288,992
  • Market Cap $6.83B
  • Description
  • Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...
More about HALO
Track This Portfolio

Track Johnson Financial Group, Inc. Portfolio

Follow Johnson Financial Group, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Johnson Financial Group, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Johnson Financial Group, Inc. with notifications on news.